BLRX vs. CLNN, NXTC, EQ, XLO, IMRX, NBRV, AADI, GANX, RMTI, and OCUP
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Clene (CLNN), NextCure (NXTC), Equillium (EQ), Xilio Therapeutics (XLO), Immuneering (IMRX), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Gain Therapeutics (GANX), Rockwell Medical (RMTI), and Ocuphire Pharma (OCUP). These companies are all part of the "pharmaceutical preparations" industry.
BioLineRx (NASDAQ:BLRX) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.
In the previous week, BioLineRx had 1 more articles in the media than Clene. MarketBeat recorded 11 mentions for BioLineRx and 10 mentions for Clene. BioLineRx's average media sentiment score of 0.60 beat Clene's score of 0.48 indicating that BioLineRx is being referred to more favorably in the media.
BioLineRx received 444 more outperform votes than Clene when rated by MarketBeat users. However, 75.95% of users gave Clene an outperform vote while only 73.36% of users gave BioLineRx an outperform vote.
1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 25.1% of Clene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
BioLineRx has a net margin of 0.00% compared to Clene's net margin of -7,873.23%. Clene's return on equity of -224.28% beat BioLineRx's return on equity.
BioLineRx presently has a consensus target price of $21.00, suggesting a potential upside of 3,011.11%. Clene has a consensus target price of $6.50, suggesting a potential upside of 1,800.03%. Given BioLineRx's higher possible upside, research analysts plainly believe BioLineRx is more favorable than Clene.
Clene has lower revenue, but higher earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
BioLineRx has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Clene has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.
Summary
Clene beats BioLineRx on 10 of the 17 factors compared between the two stocks.
Get BioLineRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
Related Companies and Tools
